Atlas Trials

Fresenius Kabi, France

1 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Fresenius Kabi, France

RecordFirmDate
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases (NCT05598684)Fresenius Kabi, France2022-11-24

Track Fresenius Kabi, France automatically

Every clearance here is in the API, with alerts when new ones post.